Elixiron Immunotherapeutics Announces Orphan Drug Designation Granted to CSF-1R Inhibitor, EI-1071 for the Treatment of Idiopathic Pulmonary Fibrosis
SAN FRANCISCO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Elixiron Immunotherapeutics, a clinical stage biotech company, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its colony stimulating factor1 receptor (CSF1R) inhibitor, EI1071 for the treatment of idiopathic pulmonary fibrosis (IPF).
- SAN FRANCISCO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Elixiron Immunotherapeutics, a clinical stage biotech company, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its colony stimulating factor1 receptor (CSF1R) inhibitor, EI1071 for the treatment of idiopathic pulmonary fibrosis (IPF).
- Idiopathic pulmonary fibrosis is a chronic interstitial lung disease characterized by tissue fibrosis and progressive decline in lung function.
- CSF1 signaling plays an important role in the regulation of pulmonary macrophages which drive inflammatory damage and tissue fibrosis in IPF.
- CSF1R blockade with EI1071 shows promising therapeutic effects, ameliorating lung fibrosis and improving respiratory functions in preclinical models of IPF.